AstraZeneca UK Limited

CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research (2022) Kotecha D, Asselbergs FW, Achenbach S, Anker SD, Atar D, Baigent C, Banerjee A, et al. Journal article Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors (2022) Poch CM, Foo KS, De Angelis MT, Jennbacken K, Santamaria G, Baehr A, Wang QD, et al. Journal article Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis (2022) Balmana J, Fasching P, Delaloge S, Park YH, Eisen A, Bourgeois H, Kemp Z, et al. Conference contribution Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial (2022) Waijer SW, Vart P, Cherney DZ, Chertow GM, Jongs N, Langkilde AM, Mann JFE, et al. Journal article Immune checkpoint inhibitors in urothelial carcinoma: Recommendations for practical approaches to pd-l1 and other potential predictive biomarker testing (2021) Lopez-Beltran A, López-Rios F, Montironi R, Wildsmith S, Eckstein M Journal article, Review article Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease (2021) McMurray JJ, Wheeler DC, Stefánsson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, et al. Journal article Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial. (2021) Wang Y, Pan Y, Li H, Amarenco P, Denison H, Evans SR, Himmelmann A, et al. Journal article PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution Dapagliflozin in Patients with Chronic Kidney Disease (2020) Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann J, et al. Journal article Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2020) Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, et al. Conference contribution